Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort
LPV/r, but not DRV/r, showed a survival benefit in patients hospitalised with COVID-19, but these findings deserve further investigation in a randomised clinical trial.
Authors
- Stefan Frent (ORCID: https://orcid.org/0000-0002-7469-6755)
- Stefan D. Mihaicuta (ORCID: https://orcid.org/0000-0001-8897-8342)
- Dóra Paróczai (ORCID: https://orcid.org/0000-0001-6792-6789)
- Ana Lascu (ORCID: https://orcid.org/0000-0003-0600-1103)
- Andreea Blidaru
- Emanuel Bobu
- András Bikov (ORCID: https://orcid.org/0000-0002-8983-740X)
- Cristian Ion Mot
Institutions
- University of Szeged (HU)
- University of Manchester (GB)
- West University of Timişoara (RO)
- Manchester University NHS Foundation Trust (GB)
- Institute e-Austria Timisoara (RO)
- Wythenshawe Hospital (GB)
Publication Details
- Journal
- Frontiers in Cellular and Infection Microbiology
- Published
- 2025-01-16
- DOI
- https://doi.org/10.3389/fcimb.2024.1496176
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Szegedi Tudományegyetem
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap